Identification of inhibitor specificity determinants in a mammalian phosphodiesterase

被引:30
作者
Atienza, JM
Susanto, D
Huang, C
McCarty, AS
Colicelli, J [1 ]
机构
[1] Univ Calif Los Angeles, Sch Med, Dept Biol Chem, Los Angeles, CA 90095 USA
[2] Univ Calif Los Angeles, Sch Med, Inst Mol Biol, Los Angeles, CA 90095 USA
关键词
D O I
10.1074/jbc.274.8.4839
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Mammalian phosphodiesterase types 3 and 4 (PDE3 and PDE4) hydrolyze cAMP and are essential for the regulation of this intracellular second messenger in many cell types. Whereas these enzymes share structural and biochemical similarities, each can be distinguished by its sensitivity to isozyme-specific inhibitors. By using a series of chimeric enzymes, we have localized the region of PDE4 that confers sensitivity to selective inhibitors. This inhibitor specificity domain lies within a short sequence at the carboxyl terminus of the catalytic domain of the protein, consistent with the competitive nature of inhibition by these compounds, Surprisingly, the identified region also includes some of the most highly conserved residues among PDE isoforms, A yeast-based expression system was used for the isolation and characterization of mutations within this area that confer resistance to the PDE4-specific inhibitor rolipram. Analysis of these mutants indicated that both conserved and unique residues are required for isoform-specific inhibitor sensitivity. In some cases, combined point mutations contribute synergistically to the reduction of sensitivity (suppression of IC50). We also report that several mutations display differential sensitivity changes with respect to distinct structural classes of inhibitors.
引用
收藏
页码:4839 / 4847
页数:9
相关论文
共 47 条
[41]  
Spina D, 1998, ADV PHARMACOL, V44, P33, DOI 10.1016/S1054-3589(08)60125-8
[42]   Phosphodiesterase (PDE)4 inhibitors: Anti-inflammatory drugs of the future? [J].
Teixeira, MM ;
Gristwood, RW ;
Cooper, N ;
Hellewell, PG .
TRENDS IN PHARMACOLOGICAL SCIENCES, 1997, 18 (05) :164-170
[43]  
TORPHY TJ, 1992, J BIOL CHEM, V267, P1798
[44]   Hydropathic analysis and mutagenesis of the catalytic domain of the cGMP-binding cGMP-specific phosphodiesterase (PDE5). cGMP versus cAMP substrate selectivity [J].
Turko, IV ;
Francis, SH ;
Corbin, JD .
BIOCHEMISTRY, 1998, 37 (12) :4200-4205
[45]   Potential roles of conserved amino acids in the catalytic domain of the cGMP-binding cGMP-specific phosphodiesterase (PDE5) [J].
Turko, IV ;
Francis, SH ;
Corbin, JD .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (11) :6460-6466
[46]  
UNDERWOOD DC, 1993, J PHARMACOL EXP THER, V266, P306
[47]   Expression, purification, and characterization of human cAMP-specific phosphodiesterase (PDE4) subtypes A, B, C, and D [J].
Wang, P ;
Myers, JG ;
Wu, P ;
Cheewatrakoolpong, B ;
Egan, RW ;
Billah, MM .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1997, 234 (02) :320-324